Liège, Belgium – 30 April 2024 – 6PM CET – Regulated Information – Hyloris Pharmaceuticals SA
(Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical
needs through reinventing existing medications, today announces that KPMG has recently replaced
its permanent representative for the Company and informed the Company Audit Committee that
additional audit work is required to finalize the 2023 ongoing audit.
Based on information communicated by KPMG to the Audit committee, it has also initiated a forensic
independent review with respect to the Qliniq transactions including internal communication and
documentation practices. Consequently, the publication of its 2023 Annual Report, originally
scheduled for release on April 30, 2024, will be delayed. Pending the review, trading of the Company's
shares will remain suspended.
On March 14th 2024, the Company issued a press release explaining the restatement of the Qliniq
transactions following a correction of a non-cash error in the 2022 accounting treatment of the
transaction. The Company does not expect to change the restated accounting treatment related to
the Qliniq transactions.
Hyloris remains committed to open communication with its investors and other stakeholders and will
provide timely updates on any material developments and a revised publication date for the Annual
Report as soon as confirmed.